The Translational Cancer Research Program in Oncology has been established at the Perkins in collaboration with Surgeons, Oncologists and Pathologists across several Perth hospitals. Our focus is on using state of the art omics technologies (including genomics, single cell sequencing, metabolomics, proteomics) to provide detailed molecular characterisation of individual cancers. In conjunction with this we have established better preclinical models to assess new cancer medicines. In particular, we have developed models that can more accurately evaluate new immunotherapy drugs.
This research will enable improved preclinical assessment of new drugs and combination therapies, leading to greater success rates for clinical trials and better outcomes for cancer patients. In addition, detailed genomic characterisation of cancers will facilitate the development of novel biomarkers needed to better monitor pharmacodynamics, predict response and resistance to specific drugs as well as enable better stratification of target populations.
Capabilities:
I. Perkins Cancer Biobank
II. Preclinical Cancer Models
All donations of $2 and over are tax deductible in Australia.
Perkins is registered with the Australian Taxation Office as a Deductible Gift Recipient (DGR): Charitable Fundraising Authority No DGR CC20761
We acknowledge the Whadjuk people of the Nyoongar nation, the traditional owners of the lands where our offices are located and pay respects to their elders, past, present and emerging.
